Management of the axilla in T1-2N1 breast cancer

In the setting where the ongoing evolution of management of the axilla in breast cancer is being driven by better understanding of different sub-types of the disease, and of how these respond to chemotherapy, here we discuss management of the axilla in breast cancer patients who present with T1 or T...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Tamer, Mahmoud, Kovacs, Tibor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9151923/
https://www.ncbi.nlm.nih.gov/pubmed/35637226
http://dx.doi.org/10.1038/s41523-022-00432-y
_version_ 1784717552288530432
author El-Tamer, Mahmoud
Kovacs, Tibor
author_facet El-Tamer, Mahmoud
Kovacs, Tibor
author_sort El-Tamer, Mahmoud
collection PubMed
description In the setting where the ongoing evolution of management of the axilla in breast cancer is being driven by better understanding of different sub-types of the disease, and of how these respond to chemotherapy, here we discuss management of the axilla in breast cancer patients who present with T1 or T2 N1 disease, while making the distinction between triple negative and HER2 positive tumors as one group, and hormone receptor positive/HER2 negative tumors as a second group.
format Online
Article
Text
id pubmed-9151923
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-91519232022-06-01 Management of the axilla in T1-2N1 breast cancer El-Tamer, Mahmoud Kovacs, Tibor NPJ Breast Cancer Comment In the setting where the ongoing evolution of management of the axilla in breast cancer is being driven by better understanding of different sub-types of the disease, and of how these respond to chemotherapy, here we discuss management of the axilla in breast cancer patients who present with T1 or T2 N1 disease, while making the distinction between triple negative and HER2 positive tumors as one group, and hormone receptor positive/HER2 negative tumors as a second group. Nature Publishing Group UK 2022-05-30 /pmc/articles/PMC9151923/ /pubmed/35637226 http://dx.doi.org/10.1038/s41523-022-00432-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Comment
El-Tamer, Mahmoud
Kovacs, Tibor
Management of the axilla in T1-2N1 breast cancer
title Management of the axilla in T1-2N1 breast cancer
title_full Management of the axilla in T1-2N1 breast cancer
title_fullStr Management of the axilla in T1-2N1 breast cancer
title_full_unstemmed Management of the axilla in T1-2N1 breast cancer
title_short Management of the axilla in T1-2N1 breast cancer
title_sort management of the axilla in t1-2n1 breast cancer
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9151923/
https://www.ncbi.nlm.nih.gov/pubmed/35637226
http://dx.doi.org/10.1038/s41523-022-00432-y
work_keys_str_mv AT eltamermahmoud managementoftheaxillaint12n1breastcancer
AT kovacstibor managementoftheaxillaint12n1breastcancer

Ejemplares similares